Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Stopped Despite our efforts, the trial faced challenges like a longer activation period and slower accrual. We proposed a redesign, but TAKEDA withdrew. As a non-profit organisation, we can't continue without TAKEDA's support and must discontinue the trial.

Conditions

• NSCLC, Stage III
• ALK-rearrangement

Interventions

• DRUG: Brigatinib
• DRUG: Durvalumab

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

• [object Object]